Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Cell Therapy Commercialization: A View from Lonza on Bioreactors
. I had the pleasure of meeting Dr. Eytan Abraham over lunch on the first day of the Till & McCulloch Meetings, held last month in Ottawa (October 27-29). After some discussion about cell therapy manufacturing, I learned that he is the new Head of Research and Technology at Lonza, based out of Walkersville, Maryland. […]
Cell Therapy Commercialization: A View from GE Healthcare on Immunotherapy
. Those following the regenerative medicine (RM) industry are likely in-tune with a rapidly evolving market, on the periphery, that is shaping up to provide a very attractive value proposition to patients, industry, and investors alike. The health care industry is undergoing a paradigm shift: Big Pharma has historically spread its efforts across palliative and substitutive […]
Update from the Clinic: September
. Welcome to your Update from the Clinic for the month of September. There’s a mixture of news from the cancer stem cell companies and immunotherapy companies this past month. Amongst other things, the FDA removed the previously imposed partial hold on one of OncoMed’s therapeutics; Opexa Therapeutics announced its next therapeutic program; and, Harvard […]
Regenerative Medicine Deal Review: September
Welcome to your deal review for the month of September. There was some healthy news flow around cell-based immunotherapy companies this past month, heating up a space that is already ablaze with activity. Undoubtedly the company that took the spotlight was Adaptimmune, which completed a venture capital (VC) round of over $100 million! The money […]
Lessons from Dendreon
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its senior debt holders, its fate remains unclear and could include […]